<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404573</url>
  </required_header>
  <id_info>
    <org_study_id>RGH-MD-03</org_study_id>
    <nct_id>NCT00404573</nct_id>
  </id_info>
  <brief_title>Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <brief_summary>
    <textblock>
      This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of
      acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment,
      and 4 weeks safety follow-up. All patients meeting the eligibility criteria will be
      randomized to one of the three treatment groups--one of two doses of RGH-188 or placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS Total Score</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RGH-188</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female inpatients, 18-65 years of age, meeting DSM-IV-TR criteria for
             schizophrenia and having a Total Positive and Negative Syndrome Scale (PANSS) Score
             &gt;=80 and &lt;=120. A score &gt;=4 on item P1 (delusions) or P3 (hallucinatory behavior) and
             a score of &gt;=4 on item P2 (conceptual disorganization) or P6
             (suspiciousness/persecution) of the PNASS

        Exclusion Criteria:

          -  Patients with documented disease of the central nervous system that can interfere with
             the trial assessments, including but not limited to stroke, tumor, Parkinson's,
             organic brain disease, seizure disorder (except for febrile convulsions during
             infancy), chronic infection, or neurosyphilis; or patients who have suffered a
             traumatic brain injury resulting in significant impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>For information regarding investigative sites, contact Forest Professional Affairs</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2006</study_first_posted>
  <last_update_submitted>January 3, 2008</last_update_submitted>
  <last_update_submitted_qc>January 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2008</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

